Keywords: Abbott, First-quarter 2010, Facet, M&A
Abbott Labs’ first quarter 2010 profits plunge, but forecasts double-digit ongoing earnings growth in 2010; completes Facet buy
Article | 22 April 2010
US health care major Abbott Laboratories reported first-quarter 20110 earnings of $1 billion, or $0.64 per share, down around 30% from the $1.44 billion, or $0.92 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
